Journal article

Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD.

  • Casén C Genetic Analysis AS, Oslo, Norway.
  • Vebø HC Genetic Analysis AS, Oslo, Norway.
  • Sekelja M Genetic Analysis AS, Oslo, Norway.
  • Hegge FT Genetic Analysis AS, Oslo, Norway.
  • Karlsson MK Genetic Analysis AS, Oslo, Norway.
  • Ciemniejewska E Genetic Analysis AS, Oslo, Norway.
  • Dzankovic S Genetic Analysis AS, Oslo, Norway.
  • Frøyland C Genetic Analysis AS, Oslo, Norway.
  • Nestestog R Genetic Analysis AS, Oslo, Norway.
  • Engstrand L Karolinska Institute, Stockholm, Sweden.
  • Munkholm P Department of Gastroenterology, Northzealand Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Nielsen OH Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Rogler G Clinic for Gastroenterology and Hepatology, University of Zürich, Zürich, Switzerland.
  • Simrén M Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Öhman L Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Vatn MH EpiGen Institute, Campus Ahus, Institute of Clinical Medicine, University of Oslo, Lørenskog, Norway.
  • Rudi K Department of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Aas, Norway.
Show more…
  • 2015-05-15
Published in:
  • Alimentary pharmacology & therapeutics. - 2015
English BACKGROUND
Dysbiosis is associated with many diseases, including irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD), obesity and diabetes. Potential clinical impact of imbalance in the intestinal microbiota suggests need for new standardised diagnostic methods to facilitate microbiome profiling.


AIM
To develop and validate a novel diagnostic test using faecal samples to profile the intestinal microbiota and identify and characterise dysbiosis.


METHODS
Fifty-four DNA probes targeting ≥300 bacteria on different taxonomic levels were selected based on ability to distinguish between healthy controls and IBS patients in faecal samples. Overall, 165 healthy controls (normobiotic reference collection) were used to develop a dysbiosis model with a bacterial profile and Dysbiosis Index score output. The model algorithmically assesses faecal bacterial abundance and profile, and potential clinically relevant deviation in the microbiome from normobiosis. This model was tested in different samples from healthy volunteers and IBS and IBD patients (n = 330) to determine the ability to detect dysbiosis.


RESULTS
Validation confirms dysbiosis was detected in 73% of IBS patients, 70% of treatment-naïve IBD patients and 80% of IBD patients in remission, vs. 16% of healthy individuals. Comparison of deep sequencing and the GA-map Dysbiosis Test, (Genetic Analysis AS, Oslo, Norway) illustrated good agreement in bacterial capture; the latter showing higher resolution by targeting pre-determined highly relevant bacteria.


CONCLUSIONS
The GA-map Dysbiosis Test identifies and characterises dysbiosis in IBS and IBD patients, and provides insight into a patient's intestinal microbiota. Evaluating microbiota as a diagnostic strategy may allow monitoring of prescribed treatment regimens and improvement in new therapeutic approaches.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/132996
Statistics

Document views: 32 File downloads:
  • fulltext.pdf: 0